Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Homology Medicines

DB:35H
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
35H
DB
$752M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Homology Medicines has significant price volatility in the past 3 months.
35H Share Price and Events
7 Day Returns
18.8%
DB:35H
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-45.1%
DB:35H
-13.2%
DE Biotechs
-20.9%
DE Market
35H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Homology Medicines (35H) 18.8% -22.9% -9.1% -45.1% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 35H underperformed the Biotechs industry which returned -13.2% over the past year.
  • 35H underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
35H
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Homology Medicines undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Homology Medicines to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Homology Medicines.

DB:35H Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:35H
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (0%))
1.126
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.126 * 5.44%)
5.73%

Discounted Cash Flow Calculation for DB:35H using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Homology Medicines is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:35H DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.73%)
2020 -126.15 Analyst x1 -119.31
2021 -150.29 Analyst x2 -134.43
2022 -146.55 Analyst x2 -123.97
2023 -82.49 Analyst x2 -66.00
2024 46.23 Analyst x2 34.98
2025 66.06 Est @ 42.89% 47.27
2026 85.81 Est @ 29.91% 58.08
2027 103.68 Est @ 20.82% 66.37
2028 118.67 Est @ 14.46% 71.84
2029 130.54 Est @ 10% 74.74
Present value of next 10 years cash flows $-90.00
DB:35H DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $130.54 × (1 + -0.39%) ÷ (5.73% – -0.39%)
$2,122.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,122.96 ÷ (1 + 5.73%)10
$1,215.51
DB:35H Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-90.00 + $1,215.51
$1,125.51
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,125.51 / 45.18
$24.91
DB:35H Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:35H represents 0.88822x of NasdaqGS:FIXX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88822x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 24.91 x 0.88822
€22.13
Value per share (EUR) From above. €22.13
Current discount Discount to share price of €14.78
= -1 x (€14.78 - €22.13) / €22.13
33.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Homology Medicines is available for.
Intrinsic value
33%
Share price is €14.78 vs Future cash flow value of €22.13
Current Discount Checks
For Homology Medicines to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Homology Medicines's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Homology Medicines's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Homology Medicines's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Homology Medicines's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:35H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.47
NasdaqGS:FIXX Share Price ** NasdaqGS (2020-04-03) in USD $16.64
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Homology Medicines.

DB:35H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FIXX Share Price ÷ EPS (both in USD)

= 16.64 ÷ -2.47

-6.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Homology Medicines is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Homology Medicines is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Homology Medicines's expected growth come at a high price?
Raw Data
DB:35H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
2.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Homology Medicines, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Homology Medicines's assets?
Raw Data
DB:35H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.73
NasdaqGS:FIXX Share Price * NasdaqGS (2020-04-03) in USD $16.64
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:35H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FIXX Share Price ÷ Book Value per Share (both in USD)

= 16.64 ÷ 5.73

2.9x

* Primary Listing of Homology Medicines.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Homology Medicines is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Homology Medicines's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Homology Medicines has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Homology Medicines expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Homology Medicines expected to grow at an attractive rate?
  • Unable to compare Homology Medicines's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Homology Medicines's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Homology Medicines's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:35H Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:35H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 2.7%
DB:35H Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 68.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:35H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:35H Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 348 -23 -54 5
2023-12-31 144 -74 -137 5
2022-12-31 29 -115 -162 5
2021-12-31 4 -120 -144 7
2020-12-31 5 -100 -124 7
2020-04-06
DB:35H Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -91 -104
2019-09-30 1 -73 -100
2019-06-30 2 -61 -85
2019-03-31 3 -49 -71
2018-12-31 5 -43 -56
2018-09-30 4 -12 -49
2018-06-30 3 -4 -41
2018-03-31 1 0 -35
2017-12-31 6 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Homology Medicines is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Homology Medicines's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:35H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Homology Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:35H Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.82 0.78 -3.30 4.00
2023-12-31 -1.95 -0.78 -3.15 4.00
2022-12-31 -2.60 -1.99 -3.29 4.00
2021-12-31 -2.63 -2.19 -3.28 7.00
2020-12-31 -2.72 -2.28 -3.30 7.00
2020-04-06
DB:35H Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.47
2019-09-30 -2.49
2019-06-30 -2.18
2019-03-31 -1.90
2018-12-31 -1.95
2018-09-30 -2.43
2018-06-30 -3.70
2018-03-31 -13.30
2017-12-31 -12.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Homology Medicines will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Homology Medicines's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Homology Medicines has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Homology Medicines performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Homology Medicines's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Homology Medicines does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Homology Medicines's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Homology Medicines's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Homology Medicines's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Homology Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:35H Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.67 -103.92 22.21
2019-09-30 0.66 -100.17 21.52
2019-06-30 1.82 -84.69 19.34
2019-03-31 2.83 -70.85 18.33
2018-12-31 5.32 -55.58 17.30
2018-09-30 4.13 -48.70 14.90
2018-06-30 2.52 -41.08 12.76
2018-03-31 1.13 -34.65 10.21
2017-12-31 -29.99 8.28
2016-12-31 -8.05 4.31 5.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Homology Medicines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Homology Medicines has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Homology Medicines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Homology Medicines's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Homology Medicines has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Homology Medicines's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Homology Medicines's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Homology Medicines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Homology Medicines's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Homology Medicines's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Homology Medicines has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Homology Medicines Company Filings, last reported 3 months ago.

DB:35H Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 258.51 0.00 262.39
2019-09-30 257.82 0.00 269.67
2019-06-30 284.74 0.00 295.80
2019-03-31 174.26 0.00 187.97
2018-12-31 196.36 0.00 214.74
2018-09-30 212.76 0.00 237.54
2018-06-30 226.80 0.00 255.51
2018-03-31 88.24 0.00 116.73
2017-12-31 98.31 0.00 129.66
2016-12-31 11.75 0.00 11.39
  • Homology Medicines has no debt.
  • Homology Medicines has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Homology Medicines has sufficient cash runway for 2.3 years based on current free cash flow.
  • Homology Medicines has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 88.8% each year.
X
Financial health checks
We assess Homology Medicines's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Homology Medicines has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Homology Medicines's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Homology Medicines dividends.
If you bought €2,000 of Homology Medicines shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Homology Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Homology Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:35H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:35H Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Homology Medicines has not reported any payouts.
  • Unable to verify if Homology Medicines's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Homology Medicines's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Homology Medicines has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Homology Medicines's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Homology Medicines afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Homology Medicines has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Homology Medicines's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arthur Tzianabos
COMPENSATION $5,062,877
AGE 56
TENURE AS CEO 4 years
CEO Bio

Dr. Arthur O. Tzianabos, Ph.D., has been the Chief Executive Officer, President and Director of Homology Medicines, Inc. since April 2016. Dr. Tzianabos serves as the Director of Stoke Therapeutics, Inc. since September 2018. Dr. Tzianabos served as the President and Chief Scientific Officer at OvaScience, Inc. from September of 2013 to March of 2016. Dr. Tzianabos served as the Chief Scientific Officer of OvaScience, Inc. from July 2013 to March 31, 2016. Dr. Tzianabos served as Vice President of Program Management, Head of Research and Early Development and Senior Vice President at Shire plc. He has more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire's acquisition of Transkaryotic Therapies, Inc. in 2005. Dr. Tzianabos joined Shire in 2005 as Senior Director, Discovery Research and was instrumental in establishing the Discovery Research group and played a leading role in the expansion of Shire HGT research pipeline shortly after the acquisition of TKT by Shire. He serves as Chair of Scientific Advisory Board at OvaScience, Inc. He has been a Member of Scientific Advisory Board at Agilis Biotherapeutics, LLC since June 2014 and as its Director since September 2015. He served as Director of ArmaGen Technologies, Inc. since December 2012. He served as a Director of bluebird bio. Prior to Shire, Dr. Tzianabos served as an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a Consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. He has been a Director of BIND Therapeutics, Inc. since October 2015. He served as a Director of DNIB Unwind, Inc. since October 2015. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease. He holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.

CEO Compensation
  • Arthur's compensation has increased whilst company is loss making.
  • Arthur's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Homology Medicines management team in years:

3
Average Tenure
55.5
Average Age
  • The tenure for the Homology Medicines management team is about average.
Management Team

Arthur Tzianabos

TITLE
President
COMPENSATION
$5M
AGE
56
TENURE
4 yrs

Brad Smith

TITLE
CFO, Treasurer & Secretary
COMPENSATION
$2M
AGE
63
TENURE
3 yrs

Albert Seymour

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
51
TENURE
4 yrs

Saswati Chatterjee

TITLE
Co-Founder & Chair of Scientific Advisory Board

Tim Kelly

TITLE
Chief Technical Operations Officer
COMPENSATION
$2M
AGE
50
TENURE
2.9 yrs

Theresa McNeely

TITLE
Chief Communications Officer & Patient Advocate
AGE
55

Gabe Cohn

TITLE
Chief Medical Officer
AGE
60
TENURE
0.3 yrs

Michael Blum

TITLE
Senior Vice President of Commercial
TENURE
0.3 yrs

Cara Mayfield

TITLE
Director of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Homology Medicines board of directors in years:

4
Average Tenure
59
Average Age
  • The tenure for the Homology Medicines board of directors is about average.
Board of Directors

Kush Parmar

TITLE
Independent Chairman
COMPENSATION
$263K
AGE
38

Arthur Tzianabos

TITLE
President
COMPENSATION
$5M
AGE
56
TENURE
4 yrs

Saswati Chatterjee

TITLE
Co-Founder & Chair of Scientific Advisory Board

Mary Thistle

TITLE
Independent Director
COMPENSATION
$233K
AGE
59
TENURE
2.1 yrs

Rich Gregory

TITLE
Independent Director
COMPENSATION
$227K
AGE
61
TENURE
5.3 yrs

Steve Gillis

TITLE
Independent Director
COMPENSATION
$223K
AGE
66
TENURE
4.3 yrs

Matt Patterson

TITLE
Independent Director
COMPENSATION
$224K
AGE
47
TENURE
2.3 yrs

Stephen Elledge

TITLE
Member of Scientific Advisory Board

Hans-Peter Kiem

TITLE
Member of Scientific Advisory Board

Mason Freeman

TITLE
Member of Scientific Advisory Board
AGE
68
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
31. Jan 20 Sell Deerfield Management Company, L.P. Company 29. Jan 20 30. Jan 20 -518,827 €14.01 €-7,267,165
28. Jan 20 Sell Deerfield Management Company, L.P. Company 24. Jan 20 28. Jan 20 -639,506 €14.33 €-9,117,190
27. Dec 19 Sell Deerfield Management Company, L.P. Company 24. Dec 19 24. Dec 19 -350,000 €19.79 €-6,926,574
23. Dec 19 Sell Deerfield Management Company, L.P. Company 19. Dec 19 23. Dec 19 -164,730 €19.69 €-3,234,811
20. May 19 Sell 5AM Venture Management LLC Company 16. May 19 16. May 19 -615,000 €19.21 €-11,814,984
15. Apr 19 Buy Deerfield Management Company, L.P. Company 12. Apr 19 12. Apr 19 533,333 €19.88 €10,604,393
X
Management checks
We assess Homology Medicines's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Homology Medicines has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Details
Name: Homology Medicines, Inc.
35H
Exchange: DB
Founded: 2015
$696,859,530
45,181,333
Website: http://www.homologymedicines.com
Address: Homology Medicines, Inc.
One Patriots Park,
Bedford,
Massachusetts, 01730,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FIXX Common Stock Nasdaq Global Select US USD 28. Mar 2018
DB 35H Common Stock Deutsche Boerse AG DE EUR 28. Mar 2018
LSE 0T6G Common Stock London Stock Exchange GB USD 28. Mar 2018
Number of employees
Current staff
Staff numbers
187
Homology Medicines employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:34
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.